Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;56(1):7-15.
doi: 10.1002/pbc.22831.

Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors

Katherine W Eaton  1 , Laura S Tooke, Luanne M Wainwright, Alexander R Judkins, Jaclyn A Biegel
Affiliations

Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors

Katherine W Eaton et al. Pediatr Blood Cancer. 2011 Jan.

Abstract

Background: Germline mutations and deletions of SMARCB1/INI1 in chromosome band 22q11.2 predispose patients to rhabdoid tumor and schwannomatosis. Previous estimates suggested that 15-20% of rhabdoid tumors were caused by an underlying germline abnormality of SMARCB1. However, these studies were limited by case selection and an inability to detect intragenic deletions and duplications.

Procedure: One hundred matched tumor and blood samples from patients with rhabdoid tumors of the brain, kidney, or soft tissues were analyzed for mutations and deletions of SMARCB1 by FISH, multiplex ligation-dependent probe amplification (MLPA), sequence analysis and high resolution Illumina 610K SNP-based oligonucleotide array studies.

Results: Thirty-five of 100 patients were found to have a germline SMARCB1 abnormality. These abnormalities included point and frameshift mutations, intragenic deletions and duplications, and larger deletions including regions both proximal and distal to SMARCB1. There were nine cases that demonstrated parent to child transmission of a mutated copy of SMARCB1. In eight of the nine cases, one or more family members were also diagnosed with rhabdoid tumor or schwannoma, and two of the eight families presented with multiple affected children in a manner consistent with gonadal mosaicism.

Conclusions: Approximately one-third of newly diagnosed patients with rhabdoid tumor have an underlying genetic predisposition to tumors due to a germline SMARCB1 alteration. Families may demonstrate incomplete penetrance and gonadal mosaicism, which must be considered when counseling families of patients with rhabdoid tumor.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Germline alterations were found in 35 cases and included mutations, duplications and deletions (shown in black). The “second hit,” found only in tumor cells, is shown in white. The last seven patients (01-135, 07-315, 00-214, 09-289, 06-147, 06-175, and 06-216) have homozygous deletions in their tumors that are the same size as germline heterozygous deletions, so they appear only as black bars.
Fig. 2
Fig. 2
Illumina Beadstudio depiction of chromosome 22 showing a heterozygous deletion in the blood of patient 08-237. A decrease in the Log R ratio corresponding to the absence of heterozygous SNPs indicates a deletion, the location of which is demonstrated by the black arrow. This deletion includes GNAZ, but not SMARCB1. The tumor shows a whole chromosome 22 deletion.
Fig. 3
Fig. 3
Pedigree of family 09-013. Two affected sisters had the same SMARCB1 exon 1 mutation (c.20_43delinsT). Neither parent had the mutation, consistent with gonadal mosaicism (A). Pedigree of family 07-367. The proband (III.1) was found to have a germline mutation in SMARCB1 exon 4 (c.472C>T), inherited from her paternal grandmother (B). Pedigree of family 08-143. The SMARCB1 exon 4 mutation (c.367C>T) was identified in two affected siblings as well as their mother. She had a de novo mutation and was subsequently diagnosed with a benign CNS lesion (C).
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Versteege I, Sévenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:203–206. - PubMed
    1. Biegel JA, Zhou J, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid rhabdoid tumors. Cancer Res. 1999;59:74–79. - PubMed
    1. Roberts CWM, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther. 2009;8:412–416. - PMC - PubMed
    1. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene. 2009;28:1653–1668. - PubMed
    1. Hornick JL, Dal Cin P, Fletcher CDM. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 2009;33:542–550. - PubMed

Publication types